TCRX vs. TNYA, SLDB, AURA, CRBU, JSPR, SOPH, OCGN, NKTX, ADPT, and MGTX
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Tenaya Therapeutics (TNYA), Solid Biosciences (SLDB), Aura Biosciences (AURA), Caribou Biosciences (CRBU), Jasper Therapeutics (JSPR), SOPHiA GENETICS (SOPH), Ocugen (OCGN), Nkarta (NKTX), Adaptive Biotechnologies (ADPT), and MeiraGTx (MGTX). These companies are all part of the "medical" sector.
Tenaya Therapeutics (NASDAQ:TNYA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Tenaya Therapeutics presently has a consensus target price of $15.40, indicating a potential upside of 264.93%. TScan Therapeutics has a consensus target price of $12.50, indicating a potential upside of 71.47%. Given TScan Therapeutics' higher probable upside, research analysts plainly believe Tenaya Therapeutics is more favorable than TScan Therapeutics.
Tenaya Therapeutics has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Tenaya Therapeutics has a net margin of 0.00% compared to Tenaya Therapeutics' net margin of -423.86%. Tenaya Therapeutics' return on equity of -60.65% beat TScan Therapeutics' return on equity.
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 33.8% of Tenaya Therapeutics shares are held by insiders. Comparatively, 8.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Tenaya Therapeutics received 4 more outperform votes than TScan Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave Tenaya Therapeutics an outperform vote while only 70.37% of users gave TScan Therapeutics an outperform vote.
TScan Therapeutics has higher revenue and earnings than Tenaya Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TScan Therapeutics had 19 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 19 mentions for TScan Therapeutics and 0 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.24 beat TScan Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.
Summary
Tenaya Therapeutics beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
